First Hawaiian Bank Has $1.67 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

First Hawaiian Bank lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 21.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,243 shares of the company’s stock after acquiring an additional 2,150 shares during the period. First Hawaiian Bank’s holdings in Neurocrine Biosciences were worth $1,671,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Everence Capital Management Inc. bought a new position in Neurocrine Biosciences in the 4th quarter valued at $476,000. GAMMA Investing LLC boosted its holdings in shares of Neurocrine Biosciences by 32.0% in the 4th quarter. GAMMA Investing LLC now owns 2,295 shares of the company’s stock worth $313,000 after buying an additional 557 shares during the last quarter. Tri Ri Asset Management Corp bought a new position in Neurocrine Biosciences during the third quarter valued at about $3,236,000. Tidal Investments LLC increased its holdings in Neurocrine Biosciences by 52.8% during the third quarter. Tidal Investments LLC now owns 15,043 shares of the company’s stock worth $1,733,000 after buying an additional 5,197 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Neurocrine Biosciences in the third quarter worth about $384,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $138.71 on Thursday. The company’s fifty day moving average price is $128.95 and its 200-day moving average price is $130.85. The firm has a market capitalization of $14.04 billion, a price-to-earnings ratio of 37.19 and a beta of 0.33. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ingrid Delaet sold 272 shares of the stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the transaction, the insider now owns 2,507 shares in the company, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,694 shares of company stock valued at $479,230 over the last 90 days. 4.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NBIX. UBS Group increased their target price on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Barclays lifted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Finally, BMO Capital Markets reduced their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday, October 17th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $164.81.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.